Cimzia - Certolizumab pegol

- Cimzia (Certolizumab pegol) is manufactured for UCB, Inc. (Smyrna, GA, USA), and was initially approved for use in the United States in 2008.[1]

Cimzia Blocks TNF-α (Tumor Necrosis Factor - alpha)

- Cimzia blocks and neutralizes the activity of TNF-α (Tumor Necrosis Factor - alpha).
- When immune cells (monocytes) are activated by Lipopolysaccharide (LPS) (a component of bacterial cells), Cimzia inhibits the Pro-Inflammatory factor TNF-α.
- Cimzia also inhibits IL-1β (InterLeukin -1 - beta), an indirect result of Cimzia's inhibition of TNF-α [1]
- Treatment with Cimzia reduces CRP (C-Reactive Protein) levels in Crohn's Disease patients.[1]

- Cimzia does not block TNF-β (Tumor Necrosis Factor - beta)[1]

- Cimzia is used for treatment in moderate to severely active Crohn's Disease (CD) or Rheumatoid Arthritis (RA).[1]

- Cimzia is given as a subcutaneous injection (injection under the skin).

Cimzia Co-Pay Savings Card

You may qualify for Cimzia savings from UCB, Inc. even if you have health insurance. To see if you qualify, please visit the Cimzia Website:[2]

Additional programs can be found here:

Clinical Trials for Cimzia

* Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) NCT01577264 Link


1. Cimzia (Certolizumab pegol) prescribing infomation.

2. Cimzia Co-Pay Savings.

3. Vilcek J and Lee TH. Tumor Necrosis Factor. New insights into the molecular mechanisms of its multiple actions. The Journal of Biological Chemistry. 1991;266(12):7313-7316.

4. Cimzia Medication Guide.

Popular Threads Discussing Cimzia

Page Tools
No one has commented on this article.

Page Tools
Search this Page

All times are GMT -5. The time now is 02:03 PM.
Copyright 2006-2017